The Periodontal Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Periodontal Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Periodontal Disease. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Periodontal Disease - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Periodontal Disease and features dormant and discontinued products.

GlobalData tracks 37 drugs in development for Periodontal Disease by 33 companies/universities/institutes. The top development phase for Periodontal Disease is preclinical with 18 drugs in that stage. The Periodontal Disease pipeline has 30 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Periodontal Disease pipeline products market are: Lighthouse Pharmaceuticals, University of Pennsylvania and Keystone Bio.

The key targets in the Periodontal Disease pipeline products market include Succinate Receptor 1 (G Protein Coupled Receptor 91 or P2Y Purinoceptor 1 Like or GPR91 or SUCNR1), Porphyromonas gingivalis Arginine Specific Cysteine Proteinase (Arg Gingipain), and Matrix Metalloproteinase (MMP or EC 3.4.24.).

The key mechanisms of action in the Periodontal Disease pipeline product include Glutaminyl Peptide Cyclotransferase (Glutaminyl Cyclase or Glutaminyl tRNA Cyclotransferase or Glutamyl Cyclase or QPCT or EC 2.3.2.5) Inhibitor with one drug in Discovery. The Periodontal Disease pipeline products include 15 routes of administration with the top ROA being Oral and eight key molecule types in the Periodontal Disease pipeline products market including Small Molecule, and Synthetic Peptide.

Periodontal Disease overview

Periodontal disease is a serious condition that affects the tissues surrounding the teeth, such as the gums, ligaments, and bone. It is caused by bacteria in dental plaque that trigger an inflammatory response in the body. If not treated, periodontal disease can lead to tooth loss, gum abscess, and other complications. Some of the symptoms of periodontal disease are red, swollen, bleeding, or receding gums, bad breath, loose teeth, and painful chewing. To prevent or treat periodontal disease, it is important to maintain good oral hygiene by brushing and flossing daily, and to visit a dentist regularly for professional cleaning and checkup. In some cases, antibiotics or surgery may be needed to control the infection and restore the health of the mouth.

For a complete picture of Periodontal Disease’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.